Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMI4EL5)

Drug Name
Ketorolac Drug Info
Synonyms
Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
Therapeutic ClassAnalgesics
Cross-matching ID
PubChem CID
3826
ChEBI ID
CHEMBL469
CAS Number
CAS 74103-06-3
TTD Drug ID
D0D9JW
INTEDE Drug ID
DR0908
ACDINA Drug ID
D00344

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.22 0.00e+0 113/158 (71.52%) RPS4Y1;RPL36;MRPS16;...
Propanoate metabolism 2.07 0.00e+0 30/34 (88.24%) ALDH6A1;ABAT;DLD;...
Natural killer cell mediated cytotoxicity 2.00 4.89e-3 99/131 (75.57%) FCGR3B;GZMB;IFNG;...
Peroxisome 1.99 3.67e-3 72/82 (87.8%) ECI2;ACSL3;AMACR;...
Neutrophil extracellular trap formation 1.98 2.93e-3 101/189 (53.44%) MPO;HAT1;FCGR3B;...
Mismatch repair 1.92 4.89e-3 22/23 (95.65%) PCNA;RPA3;LIG1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.86 8.38e-3 79/89 (88.76%) RASGRP1;IFNG;NFATC3;...
T cell receptor signaling pathway 1.86 1.10e-2 93/104 (89.42%) RASGRP1;IFNG;PAK1;...
Lysine degradation 1.83 1.30e-2 51/63 (80.95%) BBOX1;PLOD2;DHTKD1;...
Oxidative phosphorylation 1.82 1.61e-2 93/133 (69.92%) NDUFB6;ATP5F1A;ATP5MC2;...
Butanoate metabolism 1.81 1.60e-2 23/28 (82.14%) ABAT;EHHADH;HADH;...
Pyruvate metabolism 1.80 1.71e-2 41/47 (87.23%) PCK1;ME2;DLD;...
Graft-versus-host disease 1.78 2.03e-2 32/42 (76.19%) GZMB;IFNG;HLA-B;...
Leukocyte transendothelial migration 1.76 2.10e-2 90/114 (78.95%) MMP9;ACTN1;ITGAM;...
Glycolysis / Gluconeogenesis 1.75 2.15e-2 56/67 (83.58%) PCK1;PGAM1;ENO1;...
Fc epsilon RI signaling pathway 1.75 2.02e-2 57/68 (83.82%) ALOX5AP;LCP2;RAC2;...
Diabetic cardiomyopathy 1.74 2.33e-2 162/203 (79.8%) MMP9;NDUFB6;RAC2;...
Nucleotide excision repair 1.73 2.53e-2 40/47 (85.11%) PCNA;RPA3;LIG1;...
Th17 cell differentiation 1.72 2.62e-2 95/107 (88.79%) IFNG;IL2RG;NFATC3;...
DNA replication 1.71 2.64e-2 34/36 (94.44%) PCNA;RPA3;LIG1;...
Non-alcoholic fatty liver disease 1.71 2.65e-2 126/155 (81.29%) LEPR;NDUFB6;CXCL8;...
Th1 and Th2 cell differentiation 1.71 2.60e-2 80/92 (86.96%) JAG1;IFNG;IL2RG;...
Prion disease 1.70 2.81e-2 209/273 (76.56%) TUBB2A;NDUFB6;HSPA2;...
Valine, leucine and isoleucine degradation 1.70 2.69e-2 42/48 (87.5%) ALDH6A1;ABAT;DLD;...
Proximal tubule bicarbonate reclamation 1.69 2.82e-2 21/23 (91.3%) SLC4A4;PCK1;GLUD2;...
Citrate cycle (TCA cycle) 1.69 2.71e-2 30/30 (100%) PCK1;DLST;DLD;...
Glyoxylate and dicarboxylate metabolism 1.69 2.77e-2 23/30 (76.67%) GLUL;DLD;ACO1;...
Type I diabetes mellitus 1.67 3.35e-2 38/43 (88.37%) GZMB;IFNG;HLA-B;...
Primary bile acid biosynthesis 1.64 4.60e-2 15/17 (88.24%) AMACR;SLC27A5;CYP46A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H